Page last updated: 2024-12-07

t 1982

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3,4,6,7,8-hexahydro-2H-pyrimido(1,2-a)pyrimidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID79873
CHEBI ID94622
SCHEMBL ID51453
MeSH IDM0109884

Synonyms (43)

Synonym
1,3,4,6,7,8-hexahydro-2h-pyrimido(1,2-a)pyrimidine
1,3,4,6,7,8-hexahydro-2h-pyrimido[1,2-a]pyrimidine
2h-pyrimido[1,2-a]pyrimidine, 1,3,4,6,7,8-hexahydro-
1,5,7-triazabicyclo[4.4.0]dec-5-ene, 98%
hhpp
FT-0690905
3,4,6,7,8,9-hexahydro-2h-pyrimido[1,2-a]pyrimidine
A831720
unii-kaf7gn82tm
2h-pyrimido(1,2-a)pyrimidine, 1,3,4,6,7,8-hexahydro-
einecs 227-367-1
kaf7gn82tm ,
5807-14-7
1,5,7-triazabicyclo[4.4.0]dec-5-ene
T1982
AKOS006222316
triazabicyclodecene
2,3,4,6,7,8-hexahydro-1h-pyrimido[1,2-a]pyrimidine
BRD-K45542213-001-01-4
CS-B0736
SCHEMBL51453
1,5,7-triazabicyclo[4.4.0]deca-5-ene
1,3,4,6,7,8,-hexahydro-2h-pyrimido(1,2-a)pyrimidine
1,5,7-triazabicyclo[4,4,0] dec-5-ene
1,5,7-triazabicyclo[4,4,0]dec-5-ene
1,5,7-triazabicyclo [4.4.0]dec-5-ene
1,5,7-triazabicyclo(4.4.0)dec-5-ene
DTXSID10206793
mfcd00043003
J-509567
1,5,7-triazabicyclo[4.4.0]dec-5-ene, purum, >=98.0% (t)
CHEBI:94622
1,5,7-triazabicylo[4.4.0]dec-5-ene
DS-15178
BCP09211
Q7840264
A930606
SY013446
PB43106
1h,2h,3h,4h,6h,7h,8h-[1,3]diazino[1,2-a]pyrimidine
EN300-267515
PD053640
HY-59156
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (15.79)29.6817
2010's16 (84.21)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.70 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]